3 results
The aim of this study is to investigate what proportion of HBeAg negative, inactive carriers of the hepatitis B virus with low (< 20,000 IU/mL) load will lose HBsAg when treated with nucleot(s)ide analogue/Peg-IFN combination therapy.
Primary objective:• To investigate whether Enhanced programming is safe for primary and secondary prevention patientsSecondary objectives:• Investigate the impact of Enhanced programming on adverse events (related to ICD shock with consequences and…
The primary objective of this study is to enable continued treatment with the study drug sonlicromanol for patients who have completed study KH176-202 and to investigate the safety and tolerability of sonlicromanol over an 12 months treatment period…